DK0889733T3 - Stabiliseret væksthormonformulering og fremgangsmåde til fremstilling deraf - Google Patents

Stabiliseret væksthormonformulering og fremgangsmåde til fremstilling deraf

Info

Publication number
DK0889733T3
DK0889733T3 DK97902109T DK97902109T DK0889733T3 DK 0889733 T3 DK0889733 T3 DK 0889733T3 DK 97902109 T DK97902109 T DK 97902109T DK 97902109 T DK97902109 T DK 97902109T DK 0889733 T3 DK0889733 T3 DK 0889733T3
Authority
DK
Denmark
Prior art keywords
growth hormone
buffer
stabilizing agent
preparation
formulation
Prior art date
Application number
DK97902109T
Other languages
Danish (da)
English (en)
Inventor
Michael Kevin Mcnamara
William Neil Charman
Susan Ann Charman
Original Assignee
Csl Ltd
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3792327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0889733(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd, Univ Monash filed Critical Csl Ltd
Application granted granted Critical
Publication of DK0889733T3 publication Critical patent/DK0889733T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97902109T 1996-02-12 1997-02-12 Stabiliseret væksthormonformulering og fremgangsmåde til fremstilling deraf DK0889733T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN8012A AUPN801296A0 (en) 1996-02-12 1996-02-12 Stabilised growth hormone formulation and method of preparation thereof
PCT/AU1997/000075 WO1997029767A1 (en) 1996-02-12 1997-02-12 Stabilised growth hormone formulation and method of preparation thereof

Publications (1)

Publication Number Publication Date
DK0889733T3 true DK0889733T3 (da) 2007-01-29

Family

ID=3792327

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97902109T DK0889733T3 (da) 1996-02-12 1997-02-12 Stabiliseret væksthormonformulering og fremgangsmåde til fremstilling deraf

Country Status (12)

Country Link
US (1) US6593296B1 (enExample)
EP (1) EP0889733B1 (enExample)
JP (1) JP4255515B2 (enExample)
CN (1) CN1132626C (enExample)
AT (1) ATE340587T1 (enExample)
AU (1) AUPN801296A0 (enExample)
CA (1) CA2246501C (enExample)
DE (1) DE69736739T2 (enExample)
DK (1) DK0889733T3 (enExample)
RU (1) RU2191029C2 (enExample)
TR (1) TR199801558T2 (enExample)
WO (1) WO1997029767A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
WO2001003741A1 (en) * 1999-07-12 2001-01-18 Grandis Biotech Gmbh Growth hormone formulations
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
KR20080011353A (ko) 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
MXPA03000073A (es) 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
JP4610154B2 (ja) * 2002-05-30 2011-01-12 大塚製薬株式会社 注射用製剤
ZA200505305B (en) * 2002-12-31 2007-07-25 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
JP4949828B2 (ja) * 2003-03-18 2012-06-13 アレス トレーディング ソシエテ アノニム 溶液中での成長ホルモンの安定化
WO2005027960A1 (en) * 2003-09-25 2005-03-31 Cangene Corporation Liquid human growth hormone formulation containing polyethylene glycol
WO2005063298A1 (en) 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation
KR101120879B1 (ko) * 2004-04-07 2012-02-27 아레스 트레이딩 에스.아. 액체 성장 호르몬 제제
DE602005009856D1 (de) 2004-11-09 2008-10-30 Ares Trading Sa Verfahren zur reinigung von fsh
LT1917276T (lt) 2005-08-26 2018-05-25 Ares Trading S.A. Glikozilinto interferono beta gavimo būdas
JP5199112B2 (ja) 2005-12-09 2013-05-15 アレス トレーディング ソシエテ アノニム Ｆｓｈ又はｆｓｈ変異体を精製するための方法
WO2008004717A1 (en) * 2006-07-06 2008-01-10 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
CN105363022A (zh) * 2006-07-06 2016-03-02 株式会社大熊 稳定的人生长激素液体制剂
KR101897534B1 (ko) 2008-04-21 2018-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 건조한 트랜스글루타미나제 조성물
EP2736490A1 (en) * 2011-07-25 2014-06-04 Sandoz AG Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
HK1225976A1 (en) * 2013-09-27 2017-09-22 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB131864A (enExample)
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
IL79552A0 (en) * 1985-07-30 1986-10-31 Int Minerals & Chem Corp Stabilization of growth promoting hormones
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
EP0303746B2 (en) 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
ATE359824T1 (de) 1992-07-31 2007-05-15 Genentech Inc Wässrige formulierung enthaltend menschliches wachstumshormon
MX9306133A (es) * 1992-10-02 1994-04-29 Kabi Pharmacia Ab Composicion que comprende una formulacion del factor de coagulacion viii, proceso para su preparacion y uso de un surfactante como estabilizador.
CN1108823C (zh) * 1993-02-23 2003-05-21 基因技术股份有限公司 运用赋形剂对有机溶剂处理的多肽的稳定化方法
US5707648A (en) * 1993-11-17 1998-01-13 Lds Technologies, Inc. Transparent liquid for encapsulated drug delivery

Also Published As

Publication number Publication date
JP4255515B2 (ja) 2009-04-15
EP0889733A4 (en) 1999-11-03
CA2246501C (en) 2012-07-10
US6593296B1 (en) 2003-07-15
WO1997029767A1 (en) 1997-08-21
JP2000504696A (ja) 2000-04-18
CN1132626C (zh) 2003-12-31
RU2191029C2 (ru) 2002-10-20
DE69736739T2 (de) 2007-08-16
TR199801558T2 (xx) 1998-11-23
EP0889733B1 (en) 2006-09-27
EP0889733A1 (en) 1999-01-13
CN1214633A (zh) 1999-04-21
AUPN801296A0 (en) 1996-03-07
CA2246501A1 (en) 1997-08-21
HK1017851A1 (en) 1999-12-03
ATE340587T1 (de) 2006-10-15
DE69736739D1 (de) 2006-11-09

Similar Documents

Publication Publication Date Title
DK0889733T3 (da) Stabiliseret væksthormonformulering og fremgangsmåde til fremstilling deraf
ES2188607T3 (es) Composiciones enzimaticas liquidas estabilizadas.
ES2196474T3 (es) Formulaciones liquidas que contienen una gonadotropina.
DE69329367D1 (de) Wachstumshormon-enthaltendeproteinformulierung
NO305281B1 (no) FremgangsmÕte for Õ lagringsstabilisere pereddiksyrel°sninger, samt stabiliserte pereddiksyrel°sninger
JPS6440433A (en) Aqueous liquid composition of thrombin
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
MX9306133A (es) Composicion que comprende una formulacion del factor de coagulacion viii, proceso para su preparacion y uso de un surfactante como estabilizador.
DE69821741D1 (de) Immunoglobulin enthaltende zusammensetzung
RU98117135A (ru) Композиция стабилизированного гормона роста и способ ее приготовления
OIKAWA et al. The role of calcium in Taka-amylase A
DE69933373D1 (de) Stabile, flüssige konzentrierte seltenerd-carboxylate
GB9928820D0 (en) Stable high glycerol liquids comprising sulfosuccinic acid monoesters
US4289764A (en) Steroid compositions
CA2463681A1 (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
KR950010911A (ko) 콘텍트 렌즈용 제제의 안정화 방법
IE49086B1 (en) Stable erythromycin solution and process therefor
KR880008810A (ko) [벤조-1,2,4-티아디아진]-1,1-디옥사이드 용해 조성물
ATE94400T1 (de) Strahlungssterilisierbare antimikrobielle salbe sowie verfahren zu deren herstellung.
RU94032143A (ru) Композиция, содержащая препарат коагуляционного фактора viii, способ ее получения и применение поверхностно-активного вещества в качестве стабилизатора
JPS5677209A (en) Iodophor composition
JPS5531028A (en) Injection
JPH02105898A (ja) 糖質分解酵素の安定化法
JPS5791197A (en) Reagent for measuring activity of substrate or enzyme
JPS57105187A (en) Stabilization of liquid pectinase